Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 18/20 | 0.55 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3412488 | 0.86 | KIT (0.60) | PRKDCPDPK1KIT | |
| SCHEMBL15006674 | 0.83 | PRKDC (0.78) | PRKDC | |
| SCHEMBL3418762 | 0.77 | PRKDC (0.53) | PRKDCPDPK1KIT | |
| SCHEMBL3405551 | 0.77 | PRKDC (0.63) | PRKDC | |
| SCHEMBL3412175 | 0.77 | PRKDC (0.53) | PRKDC | |
| SCHEMBL3407296 | 0.77 | PRKDC (0.68) | PRKDC | |
| SCHEMBL15006698 | 0.76 | PRKDC (0.67) | PRKDC | |
| SCHEMBL3408547 | 0.75 | PRKDC (0.51) | PRKDCPDPK1 | |
| SCHEMBL3425631 | 0.75 | PRKDC (0.63) | PRKDC | |
| SCHEMBL20031060 | 0.75 | PRKDC (0.63) | PRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588457-B1 | PYRAZOLOQUINOLINE DERIVATIVES AS DNA-PK INHIBITORS | MERCK PATENT GMBH (DE) | 2014-11-05 | — | — | EP | disclosed |
| EP-2588457-B1 | PYRAZOLOQUINOLINE DERIVATIVES AS DNA-PK INHIBITORS | MERCK PATENT GMBH (DE) | 2014-11-05 | — | — | EP | disclosed |
| US-8802712-B2 | Pyrazoloquinolines | MERCK PATENT GMBH (DE) | 2014-08-12 | — | — | US | disclosed |
| US-8802712-B2 | Pyrazoloquinolines | MERCK PATENT GMBH (DE) | 2014-08-12 | — | — | US | disclosed |
| US-20130150359-A1 | PYRAZOLOQUINOLINES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-06-13 | — | — | US | disclosed |
| US-20130150359-A1 | PYRAZOLOQUINOLINES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-06-13 | — | — | US | disclosed |
| US-20130150359-A1 | PYRAZOLOQUINOLINES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-06-13 | — | — | US | disclosed |
| WO-2012000632-A1 | PYRAZOLO-QUINOLINES | MERCK PATENT GMBH (DE) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150359-A1 | PYRAZOLOQUINOLINES | PLK1, PKN3, PKN1 | PRKDC 302/4885PDPK1 67/4885KIT 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.